Citation Impact
Citing Papers
Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites
2009 StandoutScience
A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling
2007 StandoutNobel
Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney
2006 StandoutNobel
Primary Prevention of Ischemic Stroke
2006
Dual Angiotensin Receptor and Neprilysin Inhibition as an Alternative to Angiotensin-Converting Enzyme Inhibition in Patients with Chronic Systolic Heart Failure: Rationale for and Design of the Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure Trial (PARADIGM-HF)
2013
Guidelines for the Primary Prevention of Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association The American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists.
2011
Symptomatic atherosclerosis is associated with an altered gut metagenome
2012
Cardiovascular prevention and blood pressure reduction
2003
Abdominal obesity and metabolic syndrome
2006 StandoutNature
Short-Term Effects of Nose-Only Cigarette Smoke Exposure on Glutathione Redox Homeostasis, Cytochrome P450 1A1/2 and Respiratory Enzyme Activities in Mice Tissues
2013 Standout
A Meta-Analysis of 94,492 Patients With Hypertension Treated With Beta Blockers to Determine the Risk of New-Onset Diabetes Mellitus
2007
Molecular genetics of human hypertension
1998
Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (the LIFE study)
2001
Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes
1989
Identification and Importance of Brown Adipose Tissue in Adult Humans
2009 Standout
Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations
2003
Infectious Burden and Risk of Stroke
2009
Metabolic syndrome and target organ damage in untreated essential hypertensives
2004
The Effect of Carvedilol on Morbidity and Mortality in Patients with Chronic Heart Failure
1996 Standout
Analysis of Randomized Controlled Trials on the Effect of Magnitude of Heart Rate Reduction on Clinical Outcomes in Patients With Systolic Chronic Heart Failure Receiving Beta-Blockers
2008
Mechanisms linking obesity with cardiovascular disease
2006 StandoutNature
Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction
1992 Standout
Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
2008
Urinary albumin excretion — A predictor of risk of cardiovascular disease A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men
1996
Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation
2005
Wound repair and regeneration
2008 StandoutNature
Common infections and the risk of stroke
2010
The Human Intestinal Microbiome in Health and Disease
2016 Standout
Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease
2005
Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years after Bariatric Surgery
2004 Standout
Prevention of coronary heart disease in clinical practice. Summary of recommendations of the Second Joint Task Force of European and other Societies* on Coronary Prevention
1998
Use of beta‐blockers in obesity hypertension: potential role of weight gain
2001
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction
1992 StandoutNature
Guidelines for the Primary Prevention of Stroke
2010
Heart Rate Reduction by If-Channel Inhibition and its Potential Role in Heart Failure with Reduced and Preserved Ejection Fraction
2009
How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis
2006
Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention1European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network.1,2Published simultaneously in the European Heart Journal 1998;19:1434–1503 and the Journal of Hypertension (Summary only) 1998;16(10).2
1998
A New Equation to Estimate Glomerular Filtration Rate
2009 Standout
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
High prevalence of cardiac and extracardiac target organ damage in refractory hypertension
2001
Multi-Ethnic Study of Atherosclerosis: Objectives and Design
2002 Standout
Electrocardiographic left ventricular hypertrophy and effects of antihypertensive drug therapy in hypertensive participants in the multiple risk factor intervention trial
1989
The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
2002
High-Normal Serum Creatinine Concentration Is a Predictor of Cardiovascular Risk in Essential Hypertension
2001
The immune system in atherosclerosis
2011 Standout
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
2017 Standout
Obesity, haemostasis and the fibrinolytic system
2002
Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis
2005
Absolute and relative changes in carotid intima???media thickness and atherosclerotic plaques during long-term antihypertensive treatment
2004
Protective and Damaging Effects of Stress Mediators
1998 Standout
Marked low‐density lipoprotein cholesterol reduction below current national cholesterol education program targets provides the greatest reduction in carotid atherosclerosis
2004
Resting Heart Rate in Cardiovascular Disease
2007 Standout
Low job control and risk of coronary heart disease in whitehall ii (prospective cohort) study
1997
Surgery for morbid obesity
2005
Gut metagenome in European women with normal, impaired and diabetic glucose control
2013 StandoutNature
Smoking as a modifier of the systolic blood pressure-induced risk of cardiovascular events and mortality: a population-based prospective study of middle-aged men
2002
Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients
2011
Prevention of Cardiovascular Disease in Persons with Type 2 Diabetes Mellitus: Current Knowledge and Rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial
2007
Renal Function and Intensive Lowering of Blood Pressure in Hypertensive Participants of the Hypertension Optimal Treatment (HOT) Study
2001
Subgroup and Per-Protocol Analysis of the Randomized European Trial on Isolated Systolic Hypertension in the Elderly
1998
Interaction of workplace demands and cardiovascular reactivity in progression of carotid atherosclerosis: population based study
1997
Myocardial contraction fraction: a volumetric index of myocardial shortening by freehand three-dimensional echocardiography
2002
Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
2003
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
1996 Standout
Atherosclerosis — An Inflammatory Disease
1999 Standout
The renal risks of smoking
1997
Surgical Intervention as a Strategy for Treatment of Obesity
2000
Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension
1998
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results
2008
Effects of metoprolol on heart rate variability in survivors of acute myocardial infarction
1993
Are we misunderstanding beta-blockers
2007
Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals
2001 Standout
Factor XIIIA Transglutaminase Crosslinks AT1 Receptor Dimers of Monocytes at the Onset of Atherosclerosis
2004
Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
2014 Standout
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Weight loss and progression of early atherosclerosis in the carotid artery: a four-year controlled study of obese subjects
1999
Effects of statins on stroke prevention in patients with and without coronary heart disease: A meta-analysis of randomized controlled trials
2004
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
The Hallmarks of Aging
2013 Standout
Proteinuria as a risk factor for cardiovascular disease and mortality in older people: a prospective study
2000
Atherosclerosis
2000 StandoutNature
Beta-blockers for hypertension
2012
Macrophage biology in development, homeostasis and disease
2013 StandoutNature
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
2008 Standout
C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients
2006
Left Ventricular Dilatation and the Risk of Congestive Heart Failure in People without Myocardial Infarction
1997
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
2004 Standout
Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status
2003
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Enhanced atherosclerosis and kidney dysfunction in eNOS–/–Apoe–/– mice are ameliorated by enalapril treatment
2000 StandoutNobel
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
2004 Standout
Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
2005
Pressure-induced arterial wall stress and atherosclerosis
1995
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Association of the Renin-Sodium Profile with the Risk of Myocardial Infarction in Patients with Hypertension
1991
On the importance of estimating renal function for cardiovascular risk assessment
2004
Gender differences in drug responses
2006
Atherosclerosis and left ventricular hypertrophy
1998
Rationale and design of a randomized, double‐blind, placebo‐controlled outcome trial of ivabradine in chronic heart failure: the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT)
2009
Heart rate per se impacts cardiac function in patients with systolic heart failure and pacing: a pilot study
2009
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease
2003 Standout
Is High-sensitivity C-reactive Protein Associated with Subclinical Peripheral Atherosclerosis?
2008
Prevalence and Clinical Correlates of Microalbuminuria in Essential Hypertension
1997
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
2007
The Risk of Cardiovascular Disease Mortality Associated With Microalbuminuria and Gross Proteinuria in Persons With Older-Onset Diabetes Mellitus
2000
β-Blockers in Chronic Heart Failure
2003
Policy: NIH to balance sex in cell and animal studies
2014 StandoutNature
Albuminuria and Cardiovascular Risk in Hypertensive Patients with Left Ventricular Hypertrophy: The LIFE Study
2003
Non-diabetic microalbuminuria, endothelial dysfunction and cardiovascular disease
2001
Calcium Antagonist Lacidipine Slows Down Progression of Asymptomatic Carotid Atherosclerosis
2002
Carotid Intima-Media Thickness and Antihypertensive Treatment
2006
Pharmacological and surgical treatment of obesity.
2004
Midwall Left Ventricular Mechanics
1996
Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus
2004 Standout
Microalbuminuria and Peripheral Arterial Disease Are Independent Predictors of Cardiovascular and All-Cause Mortality, Especially Among Hypertensive Subjects
1999
Guidelines for the Primary Prevention of Stroke
2014 Standout
The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes
2006
The physiological determinants and risk correlations of elevated heart rate
1999
Meta-analysis: β-Blocker Dose, Heart Rate Reduction, and Death in Patients With Heart Failure
2009
Kuopio Atherosclerosis Prevention Study (KAPS)
1995
Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure
1984 Standout
Prediction of Cardiac Structure and Function by Repeated Clinic and Ambulatory Blood Pressure
1997
Metabolic Syndrome Is Associated With Aortic Stiffness in Untreated Essential Hypertension
2005
Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation
1999
Beta-blockers for hypertension
2017
First-line drugs for hypertension
2018
Supernormal contractility in primary hypertension without left ventricular hypertrophy.
1988
Mortality and Morbidity Reduction With Candesartan in Patients With Chronic Heart Failure and Left Ventricular Systolic Dysfunction
2004
Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A
1997 StandoutNobel
Clinical Implications of Obesity With Specific Focus on Cardiovascular Disease
2004
Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses.
1999
Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.
1989
Arterial Hypertension, Microalbuminuria, and Risk of Ischemic Heart Disease
2000
Microalbuminuria and Carotid Artery Intima-Media Thickness in Nondiabetic and NIDDM Subjects
1997
Blood Pressure Lowering in Type 2 Diabetes
2015
Hypothesis: β-Adrenergic Receptor Blockers and Weight Gain
2001
Effects of Intensive Glucose Lowering in Type 2 Diabetes
2008 Standout
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease
2003
Meta-Analysis: Surgical Treatment of Obesity
2005 Standout
Heart Rate Variability
1996 Standout
The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation
2002
Reversal of Left Ventricular Hypertrophy in Essential Hypertension
1996
Effects of Statins on Progression of Carotid Atherosclerosis as Measured By Carotid Intimal—Medial Thickness: A Meta-Analysis of Randomized Controlled Trials
2010
Microalbuminuria as a Risk Predictor in Diabetes: The Continuing Saga
2014
ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol
2002
Arterial and Cardiac Aging: Major Shareholders in Cardiovascular Disease Enterprises
2003 Standout
Infectious Burden and Carotid Plaque Thickness
2010
1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension
1999 Standout
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
2002 Standout
Fibrinogen and Silent Atherosclerosis in Subjects With Cardiovascular Risk Factors
1995
Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
1998
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
2010 Standout
Beneficial effects of long-term beta-blockade in congestive cardiomyopathy.
1980
Different Effects of Antihypertensive Regimens Based on Fosinopril or Hydrochlorothiazide With or Without Lipid Lowering by Pravastatin on Progression of Asymptomatic Carotid Atherosclerosis
2004
Preclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis
2006
Works of John Wikstrand being referenced
Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertensionAddition of felodipine or ramipril to long-term treatment with β-blockade
1995
Metoprolol-induced reduction in postinfarction mortality: pooled results from five double-blind randomized trials
1992
Withdrawal of antihypertensive drug treatment: time-course for redevelopment of hypertension and effects upon left ventricular mass
1992
Metoprolol controlled release/extended release in patients with severe heart failure
2001
Carotid artery wall morphology, haemostatic factors and cardiovascular disease. An ultrasound study in men at high and low risk for atherosclerotic disease
1994
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker?
2005
High apoB/apoA-I ratio is associated with increased progression rate of carotid artery intima-media thickness in clinically healthy 58-year-old men: Experiences from very long-term follow-up in the AIR study
2008
Primary Prevention of Sudden Cardiovascular Death in Hypertensive Patients: Mortality Results From the MAPHY Study
1991
Usefulness of Microalbuminuria in Predicting Cardiovascular Mortality in Treated Hypertensive Men With and Without Diabetes Mellitus
1997
Effect of L-arginine infusion in normotensive subjects with and without a family history of hypertension
1999
Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: Experiences from MERIT-HF
2005
Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial
2001
Effects of metoprolol CR/XL on mortality and hospitalizations in patients with heart failure and history of hypertension
2002
Heart rate variability in obesity and the effect of weight loss
1999
Methodological considerations of ultrasound investigation of intima‐media thickness and lumen diameter
1994
Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure
2002
Metoprolol CR/XL in black patients with heart failure (from the Metoprolol CR/XL randomized intervention trial in chronic heart failure)
2003
A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): Study design and baseline characteristics
2005
Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptide
2009
Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study
1988
Relationship between C-reactive protein and intima-media thickness in the carotid and femoral arteries and to antibodies against oxidized low-density lipoprotein in healthy men: the Atherosclerosis and Insulin Resistance (AIR) study
2001
Decreased coronary heart disease in hypertensive smokers. Mortality results from the MAPHY study.
1989
Primary Prevention With Metoprolol in Patients With Hypertension
1988
Blood Pressure and Renal Function
1980
Effects of subpressor doses of angiotensin II on renal hemodynamics in relation to blood pressure.
1983
Predictors of Cardiovascular Morbidity in Treated Hypertension: Results from the Primary Preventive Trial in Goteborg, Sweden
1985
Noninvasive quantification of atherosclerotic lesions. Reproducibility of ultrasonographic measurement of arterial wall thickness and plaque size.
1992
Chlamydia pneumoniae but Not Cytomegalovirus Antibodies Are Associated With Future Risk of Stroke and Cardiovascular Disease
1999
Antihypertensive treatment with metoprolol or hydrochlorothiazide in patients aged 60 to 75 years. Report from a double-blind international multicenter study
1986
Urinary albumin excretion is associated with the intima-media thickness of the carotid artery in hypertensive males with non-insulin-dependent diabetes mellitus
1995
Insulin Sensitivity and Hemostatic Factors in Clinically Healthy 58-year-old Men
2000
Value of systolic and diastolic time intervals. Studies in normotensive and hypertensive 50-year-old men and in patients after myocardial infarction.
1978
Dyspnoea of cardiac origin in 67 year old men: (2). Relation to diastolic left ventricular function and mass. The study of men born in 1913.
1988
Left ventricular wall stress and systolic function in untreated primary hypertension.
1985
Low-Dose Metoprolol CR/XL and Fluvastatin Slow Progression of Carotid Intima-Media Thickness
2001
Frontiers in cardiovascular science. Quantitative measurements of atherosclerotic manifestations in humans.
1992
Left Ventricular Mass in Middle-Aged Men Relationship to blood pressure, sympathetic nervous activity, hormonal and metabolic factors
1983
Metoprolol CR/XL in Female Patients With Heart Failure
2002
Antihypertensive Treatment With Metoprolol or Hydrochlorothiazide in Patients Aged 60 to 75 Years
1986
Diastolic function of the heart in untreated primary hypertension.
1984
Tolerability of β-Blocker Initiation and Titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
2002
Dyspnoea of cardiac origin in 67 year old men: (1). Relation to systolic left ventricular function and wall stress. The study of men born in 1913.
1988
Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY Study.
1991
Atherosclerotic Changes in the Carotid Artery Bulb as Measured by B-Mode Ultrasound Are Associated With the Extent of Coronary Atherosclerosis
1997
Distortion of non-invasive cardiac pulse curves. A capillary-damped pick-up and a calibration unit forapex cardiograms and other pulse curves.
1977
Antibody Titers Against Oxidized LDL Are Not Elevated in Patients With Familial Hypercholesterolemia
1998
Oxidized low‐density lipoprotein in plasma is a prognostic marker of subclinical atherosclerosis development in clinically healthy men
2004
Regression of cardiovascular structural changes by antihypertensive treatment. Functional consequences and time course of reversal as judged from clinical studies.
1984
Primary Prevention With Metoprolol in Patients With Hypertension-Reply
1988